Related Experiment Video

Updated: Jun 27, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

ATP-noncompetitive inhibitors of CDK-cyclin complexes

Mar Orzáez1, Anna Gortat, Laura Mondragón

  • 1Department of Medicinal Chemistry, Centro de Investigación Príncipe Felipe, Avda. Autopista del Saler 16, 46012, Valencia, Spain. morzaez@cipf.es

Chemmedchem
|November 29, 2008
PubMed

Insights

Cyclin-dependent kinases (CDKs) regulate cell division and are implicated in diseases like cancer. This review explores novel ATP-noncompetitive inhibitors targeting CDK-cyclin complexes for more selective cancer therapies.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Pharmacology

Background:

  • Cell division cycle progression is governed by cyclin-dependent kinases (CDKs) interacting with cyclins.
  • Dysregulated CDK activity is linked to infectious, neurodegenerative, and proliferative diseases, notably cancer.
  • CDKs are a primary target for developing novel cancer therapeutics due to frequent mutations in cancer cells.

Purpose of the Study:

  • To review advancements in the development of ATP-noncompetitive inhibitors for CDK-cyclin complexes.
  • To highlight strategies for discovering more effective and selective CDK inhibitors.

Main Methods:

  • Review of genetic and crystallographic approaches.
  • Analysis of ATP-antagonist inhibitors and their limitations.
  • Exploration of CDK-cyclin complex formation and activation mechanisms.

Main Results:

  • ATP-competitive CDK inhibitors face challenges due to conserved ATP binding sites, limiting specificity.
  • Understanding CDK-cyclin complex mechanisms offers new avenues for drug discovery.
  • Progress has been made in developing ATP-noncompetitive CDK-cyclin inhibitors.

Conclusions:

  • Targeting CDK-cyclin complexes with non-ATP-competitive inhibitors offers a promising strategy for cancer therapy.
  • Further research into CDK-cyclin interactions is crucial for developing selective and potent drugs.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...